About MSD
MSD Pharmaceuticals Private Limited is an affiliate of Merck & Co. Inc., USA. (also known as Merck Sharp & Dohme or MSD in many parts of the world), a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck Sharp & Dohme currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

With global headquarters in New Jersey, USA, Merck & Co. Inc. 2007 sales stood at US $24.2 billion with 59,800 employees and product sales spanning 140 countries worldwide. The Merck Manufacturing Division employs more than 12, 000 people at locations in 25 countries.

Merck & Co. Inc., USA success has always been based on innovation and scientific research. A commitment to excellence in research is at the heart of its philosophy and strategy. Since the founding of its research laboratories over 70 years ago, Merck & Co. Inc. has developed more than 100 new medicines and vaccines.

The Merck Research Laboratories employs approximately 9,500 people at sites in the United States, Canada, Europe and Asia. In 2007 Merck & Co. Inc. invested US $4.9 billion in R&D.

Currently Merck's priority areas of focus in therapeutic research include Alzheimer's disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines obesity, oncology, pain, and sleep disorders. These therapeutic areas were carefully chosen based on a set of criteria including unmet medical needs, scientific opportunity and commercial opportunity. Within these therapeutic areas, Merck & Co. Inc. has committed resources to achieve research breadth and depth and to develop best-in-class targeted and differentiated products that are valued highly by patients, payers and physicians.

Merck & Co. Inc. has one of the strongest pipelines of products globally. Some of the representative products are:
  • COZAAR™ / HYZAAR® -medicines in the cardiovascular area
  • GARDASIL® medicine in the vaccine area
  • JANUVIA® medicine in the metabolics area
  • SINGULAIR® medicine in the respiratory area
  • VYTORIN® and ZETIA™ medicines in the cardiovascular area through the MSD/Schering-Plough joint venture
Merck & Co. Inc. embraces a commitment to its stakeholders, employees, neighbors, and others in the global communities where it lives and works. Its commitment is demonstrated by its work in more than 140 countries worldwide, through its philanthropic initiatives and ethical business practices.

For over 100 years MSD has produced The Merck Manual, one of many initiatives to in form health related decision making that also include the Merck Institute of Aging & Health and the Merck Vaccine Network.

Merck & Co. Inc. build high environmental and safety standards into all of their processes and activities and promote continuous improvement.

MSD was incorporated in India on 3rd December 2004. Since then the company has moved quickly in laying the foundation for a successful business in India. A business that is differentiated by its focus on putting patients first and launching innovative products those are relevant to India.

MSD currently operates within three therapeutic areas, namely critical care, metabolic and vaccines. The company initiatives and new drugs address unmet medical needs for India.

In addition to setting up a sales and marketing structure to market its best in class products in India, MSD is also coordinating research projects with clinical investigators in India's leading hospitals and universities.

As a testimonial to MSD's scientific excellence the Indian Council of Medical Research (ICMR) has signed the first public private partnership with MSD.

MSD currently employs more than 600 Indian professionals and has aggressive plans for growth.

S.No. Date Position Location

Content provided by MSD Pharmaceuticals Pvt.Ltd. Info Edge India Limited disclaims all warranties against infringement